References
14. Institute of Medicine Committee on Advancing Pain Research, Care, and Education. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. In. Washington (DC): National Academies Press (US); 2011. 15. Dowell D, Haegerich T, Chou R. No Shortcuts to Safer Opioid Prescribing. N Engl J Med. 2019;380(24):2285-2287. 16. U.S. Food and Drug Administration. FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering: FDA drug safety communication. https://www.fda.gov/drugs/drug-safety-and- availability/fda-identifies-harm-reported- sudden-discontinuation-opioid-pain-medicines- and-requires-label-changes Published April 9, 2019. Accessed August 17, 2021. 17. Kroenke K, Alford DP, Argoff C, et al. Challenges with Implementing the Centers for Disease Control and Prevention Opioid Guideline: A Consensus Panel Report. Pain Med. 2019;20(4):724-735. 18. Substance Abuse and Mental Health Services Administration. Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series 63. Publication No. PEP20-02-01-006. Rockville, MD: Substance Abuse and Mental Health Services Administration. Published 2020. Accessed. 19. Chou R, Hartung D, Turner J, et al. Opioid Treatments for Chronic Pain. Comparative Effectiveness Review No. 229. (Prepared by the Pacific Northwest Evidence-based Practice Center under Contract No. 290-2015-00009- I.) AHRQ Publication No. 20-EHC011. Rockville, MD: Agency for Healthcare Research and Quality; April 2020. 20. Department of Veterans Affairs, Department of Defense. VA/DoD Clinical Practice Guideline for Opioid Therapy for Chronic Pain. 2017. 21. Raja SN, Carr DB, Cohen M, et al. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. Pain. 2020;161(9):1976-1982. 22. Tighe P, Buckenmaier CC, 3rd, Boezaart AP, et al. Acute Pain Medicine in the United States: A Status Report. Pain Med. 2015;16(9):1806- 1826. 23. Scholz J, Finnerup NB, Attal N, et al. The IASP classification of chronic pain for ICD-11: chronic neuropathic pain. Pain. 2019;160(1):53-59. 24. Nicholas M, Vlaeyen JWS, Rief W, et al. The IASP classification of chronic pain for ICD-11: chronic primary pain. Pain. 2019;160(1):28-37. 25. Raffaeli W, Tenti M, Corraro A, et al. Chronic Pain: What Does It Mean? A Review on the Use of the Term Chronic Pain in Clinical Practice. J Pain Res. 2021;14:827-835. 26. American Medical Association. AMA urges CDC to revise opioid prescribing guideline [Press Release]. https://www.ama-assn.org/press- center/press-releases/ama-urges-cdc-revise- opioid-prescribing-guideline Published June 18, 2020. Accessed April 19, 2021.
27. Centers for Disease Control and Prevention. 2018 Annual Surveillance Report of Drug- Related Risks and Outcomes — United States. Surveillance Special Report. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. https://www.cdc. gov/drugoverdose/pdf/pubs/2018-cdc-drug- surveillance-report.pdf. Published August 31, 2018. Accessed April 6, 2021. 28. U.S. Food and Drug Administration. Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS). https://www.fda.gov/drugs/information- drug-class/opioid-analgesic-risk-evaluation- and-mitigation-strategy-rems - top. Published September 27, 2018. Accessed. 29. Tick H, Nielsen A, Pelletier KR, et al. The Pain Task Force of the Academic Consortium for Integrative Medicine and Health. Evidence-based Nonpharmacologic Strategies for Comprehensive Pain Care. A Consortium Pain Task Force White Paper http://nonpharmpaincare.org/. Published December 15, 2017. Accessed 3-6-18. 30. Skelly AC CR, Dettori JR, et al. Noninvasive Nonpharmacological Treatment for Chronic Pain: A Systematic Review. Comparative Effectiveness Review No. 209. (Prepared by the Pacific Northwest Evidence-based Practice Center under Contract No. 290-2015-00009-I.) AHRQ Publication No 18-EHC013-EF. Rockville, MD: Agency for Healthcare Research and Quality; June 2018. 31. Crawford C, Boyd C, Paat CF, et al. The Impact of Massage Therapy on Function in Pain Populations-A Systematic Review and Meta- Analysis of Randomized Controlled Trials: Part I, Patients Experiencing Pain in the General Population. Pain Med. 2016;17(7):1353-1375. 32. Gatchel RJ, Peng YB, Peters ML, Fuchs PN, Turk DC. The biopsychosocial approach to chronic pain: scientific advances and future directions. Psychol Bull. 2007;133(4):581-624. 33. Bushnell MC, Ceko M, Low LA. Cognitive and emotional control of pain and its disruption in chronic pain. Nat Rev Neurosci. 2013;14(7):502- 511. 34. Vranceanu AM, Bachoura A, Weening A, Vrahas M, Smith RM, Ring D. Psychological factors predict disability and pain intensity after skeletal trauma. J Bone Joint Surg Am. 2014;96(3):e20. 35. Lerman SF, Rudich Z, Brill S, Shalev H, Shahar G. Longitudinal associations between depression, anxiety, pain, and pain-related disability in chronic pain patients. Psychosom Med. 2015;77(3):333-341. 36. Cherkin DC, Sherman KJ, Balderson BH, et al. Effect of Mindfulness-Based Stress Reduction vs Cognitive Behavioral Therapy or Usual Care on Back Pain and Functional Limitations in Adults With Chronic Low Back Pain: A Randomized Clinical Trial. JAMA. 2016;315(12):1240-1249. 37. McCracken LM, Vowles KE. Acceptance and commitment therapy and mindfulness for chronic pain: model, process, and progress. Am Psychol. 2014;69(2):178-187.
1. U.S. Department of Health and Human Services. Pain Management Best Practices Inter- Agency Task Force Report: Updates, Gaps, Inconsistencies, and Recommendations (Final Report). https://www.hhs.gov/ash/advisory- committees/pain/index.html Published May 9, 2019. Accessed September 1, 2021. 2. Nahin RL. Severe Pain in Veterans: The Effect of Age and Sex, and Comparisons With the General Population. J Pain. 2017;18(3):247-254. 3. Gereau RWIV, Sluka KA, Maixner W, et al. A Pain Research Agenda for the 21st Century. J Pain. 2014;15(12):1203-1214. 4. Hedegaard H, Warner M, Minino AM. Drug Overdose Deaths in the United States, 1999- 2016. NCHS Data Brief. 2017(294):1-8. 5. National Institute on Drug Abuse. Overdose Death Rates. https://www.drugabuse.gov/ related-topics/trends-statistics/overdose-death- rates. Updated January 2021. Accessed July 30, 2021. 6. Office of the Surgeon General. U.S. Surgeon General’s Advisory on Naloxone and Opioid Overdose. https://www.hhs.gov/surgeongeneral/ priorities/opioids-and-addiction/naloxone- advisory/index.html - ftn1. Published April 5, 2018. Accessed March 26, 2021. 7. Centers for Disease Control and Prevention. Increase in Fatal Drug Overdoses Across the United States Driven by Synthetic Opioids Before and During the COVID-19 Pandemic. CDC Health Alert Network. https://emergency.cdc.gov/ han/2020/han00438.asp. Published December 17, 2020. Accessed August 31, 2021. 8. Florence CS, Zhou C, Luo F, Xu L. The Economic Burden of Prescription Opioid Overdose, Abuse, and Dependence in the United States, 2013. Med Care. 2016;54(10):901-906. 9. Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain. 2015;156(4):569-576. 10. Muhuri PK, Gfroerer JC, Davies MC. Associations of Nonmedical Pain Reliever Use and Initiation of Heroin Use in the United States. https://www. samhsa.gov/data/sites/default/files/DR006/ DR006/nonmedical-pain-reliever-use-2013. htm. Published August 2013. Accessed May 12, 2021. 11. Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA Psychiatry. 2014;71(7):821-826. 12. Carlson RG, Nahhas RW, Martins SS, Daniulaityte R. Predictors of transition to heroin use among initially non-opioid dependent illicit pharmaceutical opioid users: A natural history study. Drug Alcohol Depend. 2016;160:127- 134. 13. National Academies of Sciences Engineering and Medicine. Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use. Washington, DC: The National Academies Press; 2017.
42
Powered by FlippingBook